Compare Revvity Inc (RVTY) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Starbucks Corp — how do they compare? Revvity Inc trades at $155.18 (market cap $16.98B), while Starbucks Corp trades at $91.73 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 6.3× Revvity Inc's market cap, and Starbucks Corp pays the higher dividend (2.7%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Starbucks Corp for 190 Days on average.
| RVTY | SBUX | |
|---|---|---|
Market Cap | $16.98B | $106.26B |
Volume | 1,456,900 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $157.36 | $108.55 |
52-Week Low | $82.26 | $78.46 |
Typical Hold Time | 12 Days | 190 Days |
Enterprise Value | $19.30B | $125.08B |
Dividend Yield | 0.18% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Starbucks (SBUX) trades at $91.66, down 2.05% amid a bearish technical outlook with support at $89 and resistance at $92. The company reported mixed quarterly results with Q2 2026 EPS beating expectations at $0.85 vs. $0.66, but Q4 2025 missed at $0.56. Recent news highlights store closures and restructuring charges of approximately $300 million as part of a strategic turnaround. Revenue growth remains modest at $37.18B for 2025, with net income margin at 5.17%.
The stock presents a cautious opportunity with analyst consensus price target of $115.50 implying 26% upside, though high P/E of 53.88 raises valuation concerns. Key risks include execution of store optimization, labor relations, and geopolitical tensions in China. Institutional sentiment is divided with 47% buy ratings, but technical indicators signal near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
